Compile Data Set for Download or QSAR
Report error Found 142 Enz. Inhib. hit(s) with all data for entry = 13170
TargetReceptor-type tyrosine-protein phosphatase N2 [1-387](Homo sapiens (Human))
Nerio Therapeutics

US Patent
LigandPNGBDBM764796(US20250257059, Example 130)
Affinity DataIC50: 1nMAssay Description:PTPN2 was produced in E. coli as a GST-TEV fusion and the GST was removed by TEV digestion, followed by additional purification to yield full-length ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/24/2025
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase N2 [1-387](Homo sapiens (Human))
Nerio Therapeutics

US Patent
LigandPNGBDBM764797(US20250257059, Example 131)
Affinity DataIC50: 1nMAssay Description:PTPN2 was produced in E. coli as a GST-TEV fusion and the GST was removed by TEV digestion, followed by additional purification to yield full-length ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/24/2025
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase N2 [1-387](Homo sapiens (Human))
Nerio Therapeutics

US Patent
LigandPNGBDBM764800(US20250257059, Example 134)
Affinity DataIC50: 1nMAssay Description:PTPN2 was produced in E. coli as a GST-TEV fusion and the GST was removed by TEV digestion, followed by additional purification to yield full-length ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/24/2025
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase N2 [1-387](Homo sapiens (Human))
Nerio Therapeutics

US Patent
LigandPNGBDBM764783(US20250257059, Example 117)
Affinity DataIC50: 1nMAssay Description:PTPN2 was produced in E. coli as a GST-TEV fusion and the GST was removed by TEV digestion, followed by additional purification to yield full-length ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/24/2025
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase N2 [1-387](Homo sapiens (Human))
Nerio Therapeutics

US Patent
LigandPNGBDBM764806(US20250257059, Example 140)
Affinity DataIC50: 2nMAssay Description:PTPN2 was produced in E. coli as a GST-TEV fusion and the GST was removed by TEV digestion, followed by additional purification to yield full-length ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/24/2025
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase N2 [1-387](Homo sapiens (Human))
Nerio Therapeutics

US Patent
LigandPNGBDBM764801(US20250257059, Example 135)
Affinity DataIC50: 2nMAssay Description:PTPN2 was produced in E. coli as a GST-TEV fusion and the GST was removed by TEV digestion, followed by additional purification to yield full-length ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/24/2025
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase N2 [1-387](Homo sapiens (Human))
Nerio Therapeutics

US Patent
LigandPNGBDBM764804(US20250257059, Example 138)
Affinity DataIC50: 2nMAssay Description:PTPN2 was produced in E. coli as a GST-TEV fusion and the GST was removed by TEV digestion, followed by additional purification to yield full-length ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/24/2025
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase N2 [1-387](Homo sapiens (Human))
Nerio Therapeutics

US Patent
LigandPNGBDBM764805(US20250257059, Example 139)
Affinity DataIC50: 2nMAssay Description:PTPN2 was produced in E. coli as a GST-TEV fusion and the GST was removed by TEV digestion, followed by additional purification to yield full-length ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/24/2025
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase N2 [1-387](Homo sapiens (Human))
Nerio Therapeutics

US Patent
LigandPNGBDBM764761(US20250257059, Example 94)
Affinity DataIC50: 2nMAssay Description:PTPN2 was produced in E. coli as a GST-TEV fusion and the GST was removed by TEV digestion, followed by additional purification to yield full-length ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/24/2025
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase N2 [1-387](Homo sapiens (Human))
Nerio Therapeutics

US Patent
LigandPNGBDBM764762(US20250257059, Example 95)
Affinity DataIC50: 2nMAssay Description:PTPN2 was produced in E. coli as a GST-TEV fusion and the GST was removed by TEV digestion, followed by additional purification to yield full-length ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/24/2025
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase N2 [1-387](Homo sapiens (Human))
Nerio Therapeutics

US Patent
LigandPNGBDBM764766(US20250257059, Example 99)
Affinity DataIC50: 2nMAssay Description:PTPN2 was produced in E. coli as a GST-TEV fusion and the GST was removed by TEV digestion, followed by additional purification to yield full-length ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/24/2025
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase N2 [1-387](Homo sapiens (Human))
Nerio Therapeutics

US Patent
LigandPNGBDBM764763(US20250257059, Example 96)
Affinity DataIC50: 2nMAssay Description:PTPN2 was produced in E. coli as a GST-TEV fusion and the GST was removed by TEV digestion, followed by additional purification to yield full-length ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/24/2025
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase N2 [1-387](Homo sapiens (Human))
Nerio Therapeutics

US Patent
LigandPNGBDBM50649520(CHEMBL5618445 | US20250257059, Example 110)
Affinity DataIC50: 2nMAssay Description:PTPN2 was produced in E. coli as a GST-TEV fusion and the GST was removed by TEV digestion, followed by additional purification to yield full-length ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/24/2025
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase N2 [1-387](Homo sapiens (Human))
Nerio Therapeutics

US Patent
LigandPNGBDBM764778(US20250257059, Example 111)
Affinity DataIC50: 2nMAssay Description:PTPN2 was produced in E. coli as a GST-TEV fusion and the GST was removed by TEV digestion, followed by additional purification to yield full-length ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/24/2025
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase N2 [1-387](Homo sapiens (Human))
Nerio Therapeutics

US Patent
LigandPNGBDBM764775(US20250257059, Example 108)
Affinity DataIC50: 2nMAssay Description:PTPN2 was produced in E. coli as a GST-TEV fusion and the GST was removed by TEV digestion, followed by additional purification to yield full-length ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/24/2025
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase N2 [1-387](Homo sapiens (Human))
Nerio Therapeutics

US Patent
LigandPNGBDBM764782(US20250257059, Example 116)
Affinity DataIC50: 2nMAssay Description:PTPN2 was produced in E. coli as a GST-TEV fusion and the GST was removed by TEV digestion, followed by additional purification to yield full-length ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/24/2025
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase N2 [1-387](Homo sapiens (Human))
Nerio Therapeutics

US Patent
LigandPNGBDBM764779(US20250257059, Example 112)
Affinity DataIC50: 2nMAssay Description:PTPN2 was produced in E. coli as a GST-TEV fusion and the GST was removed by TEV digestion, followed by additional purification to yield full-length ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/24/2025
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase N2 [1-387](Homo sapiens (Human))
Nerio Therapeutics

US Patent
LigandPNGBDBM764780(US20250257059, Example 113)
Affinity DataIC50: 2nMAssay Description:PTPN2 was produced in E. coli as a GST-TEV fusion and the GST was removed by TEV digestion, followed by additional purification to yield full-length ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/24/2025
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase N2 [1-387](Homo sapiens (Human))
Nerio Therapeutics

US Patent
LigandPNGBDBM764769(US20250257059, Example 102)
Affinity DataIC50: 2nMAssay Description:PTPN2 was produced in E. coli as a GST-TEV fusion and the GST was removed by TEV digestion, followed by additional purification to yield full-length ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/24/2025
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase N2 [1-387](Homo sapiens (Human))
Nerio Therapeutics

US Patent
LigandPNGBDBM764768(US20250257059, Example 101)
Affinity DataIC50: 2nMAssay Description:PTPN2 was produced in E. coli as a GST-TEV fusion and the GST was removed by TEV digestion, followed by additional purification to yield full-length ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/24/2025
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase N2 [1-387](Homo sapiens (Human))
Nerio Therapeutics

US Patent
LigandPNGBDBM764773(US20250257059, Example 106)
Affinity DataIC50: 2nMAssay Description:PTPN2 was produced in E. coli as a GST-TEV fusion and the GST was removed by TEV digestion, followed by additional purification to yield full-length ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/24/2025
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase N2 [1-387](Homo sapiens (Human))
Nerio Therapeutics

US Patent
LigandPNGBDBM764774(US20250257059, Example 107)
Affinity DataIC50: 2nMAssay Description:PTPN2 was produced in E. coli as a GST-TEV fusion and the GST was removed by TEV digestion, followed by additional purification to yield full-length ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/24/2025
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase N2 [1-387](Homo sapiens (Human))
Nerio Therapeutics

US Patent
LigandPNGBDBM764793(US20250257059, Example 127)
Affinity DataIC50: 2nMAssay Description:PTPN2 was produced in E. coli as a GST-TEV fusion and the GST was removed by TEV digestion, followed by additional purification to yield full-length ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/24/2025
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase N2 [1-387](Homo sapiens (Human))
Nerio Therapeutics

US Patent
LigandPNGBDBM764790(US20250257059, Example 124)
Affinity DataIC50: 2nMAssay Description:PTPN2 was produced in E. coli as a GST-TEV fusion and the GST was removed by TEV digestion, followed by additional purification to yield full-length ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/24/2025
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase N2 [1-387](Homo sapiens (Human))
Nerio Therapeutics

US Patent
LigandPNGBDBM764757(US20250257059, Example 90)
Affinity DataIC50: 2nMAssay Description:PTPN2 was produced in E. coli as a GST-TEV fusion and the GST was removed by TEV digestion, followed by additional purification to yield full-length ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/24/2025
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase N2 [1-387](Homo sapiens (Human))
Nerio Therapeutics

US Patent
LigandPNGBDBM764791(US20250257059, Example 125)
Affinity DataIC50: 2nMAssay Description:PTPN2 was produced in E. coli as a GST-TEV fusion and the GST was removed by TEV digestion, followed by additional purification to yield full-length ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/24/2025
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase N2 [1-387](Homo sapiens (Human))
Nerio Therapeutics

US Patent
LigandPNGBDBM764794(US20250257059, Example 128)
Affinity DataIC50: 2nMAssay Description:PTPN2 was produced in E. coli as a GST-TEV fusion and the GST was removed by TEV digestion, followed by additional purification to yield full-length ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/24/2025
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase N2 [1-387](Homo sapiens (Human))
Nerio Therapeutics

US Patent
LigandPNGBDBM764795(US20250257059, Example 129)
Affinity DataIC50: 2nMAssay Description:PTPN2 was produced in E. coli as a GST-TEV fusion and the GST was removed by TEV digestion, followed by additional purification to yield full-length ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/24/2025
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase N2 [1-387](Homo sapiens (Human))
Nerio Therapeutics

US Patent
LigandPNGBDBM764785(US20250257059, Example 119)
Affinity DataIC50: 2nMAssay Description:PTPN2 was produced in E. coli as a GST-TEV fusion and the GST was removed by TEV digestion, followed by additional purification to yield full-length ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/24/2025
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase N2 [1-387](Homo sapiens (Human))
Nerio Therapeutics

US Patent
LigandPNGBDBM764789(US20250257059, Example 123)
Affinity DataIC50: 2nMAssay Description:PTPN2 was produced in E. coli as a GST-TEV fusion and the GST was removed by TEV digestion, followed by additional purification to yield full-length ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/24/2025
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase N2 [1-387](Homo sapiens (Human))
Nerio Therapeutics

US Patent
LigandPNGBDBM764752(US20250257059, Example 85)
Affinity DataIC50: 2nMAssay Description:PTPN2 was produced in E. coli as a GST-TEV fusion and the GST was removed by TEV digestion, followed by additional purification to yield full-length ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/24/2025
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase N2 [1-387](Homo sapiens (Human))
Nerio Therapeutics

US Patent
LigandPNGBDBM764786(US20250257059, Example 120)
Affinity DataIC50: 2nMAssay Description:PTPN2 was produced in E. coli as a GST-TEV fusion and the GST was removed by TEV digestion, followed by additional purification to yield full-length ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/24/2025
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase N2 [1-387](Homo sapiens (Human))
Nerio Therapeutics

US Patent
LigandPNGBDBM764787(US20250257059, Example 121)
Affinity DataIC50: 2nMAssay Description:PTPN2 was produced in E. coli as a GST-TEV fusion and the GST was removed by TEV digestion, followed by additional purification to yield full-length ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/24/2025
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase N2 [1-387](Homo sapiens (Human))
Nerio Therapeutics

US Patent
LigandPNGBDBM764808(US20250257059, Example 142)
Affinity DataIC50: 3nMAssay Description:PTPN2 was produced in E. coli as a GST-TEV fusion and the GST was removed by TEV digestion, followed by additional purification to yield full-length ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/24/2025
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase N2 [1-387](Homo sapiens (Human))
Nerio Therapeutics

US Patent
LigandPNGBDBM764776(US20250257059, Example 109)
Affinity DataIC50: 3nMAssay Description:PTPN2 was produced in E. coli as a GST-TEV fusion and the GST was removed by TEV digestion, followed by additional purification to yield full-length ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/24/2025
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase N2 [1-387](Homo sapiens (Human))
Nerio Therapeutics

US Patent
LigandPNGBDBM764807(US20250257059, Example 141)
Affinity DataIC50: 3nMAssay Description:PTPN2 was produced in E. coli as a GST-TEV fusion and the GST was removed by TEV digestion, followed by additional purification to yield full-length ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/24/2025
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase N2 [1-387](Homo sapiens (Human))
Nerio Therapeutics

US Patent
LigandPNGBDBM764798(US20250257059, Example 132)
Affinity DataIC50: 3nMAssay Description:PTPN2 was produced in E. coli as a GST-TEV fusion and the GST was removed by TEV digestion, followed by additional purification to yield full-length ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/24/2025
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase N2 [1-387](Homo sapiens (Human))
Nerio Therapeutics

US Patent
LigandPNGBDBM764799(US20250257059, Example 133)
Affinity DataIC50: 3nMAssay Description:PTPN2 was produced in E. coli as a GST-TEV fusion and the GST was removed by TEV digestion, followed by additional purification to yield full-length ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/24/2025
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase N2 [1-387](Homo sapiens (Human))
Nerio Therapeutics

US Patent
LigandPNGBDBM764771(US20250257059, Example 104)
Affinity DataIC50: 3nMAssay Description:PTPN2 was produced in E. coli as a GST-TEV fusion and the GST was removed by TEV digestion, followed by additional purification to yield full-length ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/24/2025
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase N2 [1-387](Homo sapiens (Human))
Nerio Therapeutics

US Patent
LigandPNGBDBM764802(US20250257059, Example 136)
Affinity DataIC50: 3nMAssay Description:PTPN2 was produced in E. coli as a GST-TEV fusion and the GST was removed by TEV digestion, followed by additional purification to yield full-length ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/24/2025
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase N2 [1-387](Homo sapiens (Human))
Nerio Therapeutics

US Patent
LigandPNGBDBM764772(US20250257059, Example 105)
Affinity DataIC50: 3nMAssay Description:PTPN2 was produced in E. coli as a GST-TEV fusion and the GST was removed by TEV digestion, followed by additional purification to yield full-length ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/24/2025
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase N2 [1-387](Homo sapiens (Human))
Nerio Therapeutics

US Patent
LigandPNGBDBM764792(US20250257059, Example 126)
Affinity DataIC50: 3nMAssay Description:PTPN2 was produced in E. coli as a GST-TEV fusion and the GST was removed by TEV digestion, followed by additional purification to yield full-length ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/24/2025
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase N2 [1-387](Homo sapiens (Human))
Nerio Therapeutics

US Patent
LigandPNGBDBM764759(US20250257059, Example 92)
Affinity DataIC50: 3nMAssay Description:PTPN2 was produced in E. coli as a GST-TEV fusion and the GST was removed by TEV digestion, followed by additional purification to yield full-length ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/24/2025
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase N2 [1-387](Homo sapiens (Human))
Nerio Therapeutics

US Patent
LigandPNGBDBM764670(US20250257059, Example 3)
Affinity DataIC50: 3nMAssay Description:PTPN2 was produced in E. coli as a GST-TEV fusion and the GST was removed by TEV digestion, followed by additional purification to yield full-length ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/24/2025
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase N2 [1-387](Homo sapiens (Human))
Nerio Therapeutics

US Patent
LigandPNGBDBM764760(US20250257059, Example 93)
Affinity DataIC50: 3nMAssay Description:PTPN2 was produced in E. coli as a GST-TEV fusion and the GST was removed by TEV digestion, followed by additional purification to yield full-length ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/24/2025
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase N2 [1-387](Homo sapiens (Human))
Nerio Therapeutics

US Patent
LigandPNGBDBM764764(US20250257059, Example 97)
Affinity DataIC50: 3nMAssay Description:PTPN2 was produced in E. coli as a GST-TEV fusion and the GST was removed by TEV digestion, followed by additional purification to yield full-length ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/24/2025
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase N2 [1-387](Homo sapiens (Human))
Nerio Therapeutics

US Patent
LigandPNGBDBM764750(US20250257059, Example 83)
Affinity DataIC50: 3nMAssay Description:PTPN2 was produced in E. coli as a GST-TEV fusion and the GST was removed by TEV digestion, followed by additional purification to yield full-length ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/24/2025
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase N2 [1-387](Homo sapiens (Human))
Nerio Therapeutics

US Patent
LigandPNGBDBM764785(US20250257059, Example 119)
Affinity DataIC50: 3nMAssay Description:PTPN2 was produced in E. coli as a GST-TEV fusion and the GST was removed by TEV digestion, followed by additional purification to yield full-length ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/24/2025
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase N2 [1-387](Homo sapiens (Human))
Nerio Therapeutics

US Patent
LigandPNGBDBM764748(US20250257059, Example 81)
Affinity DataIC50: 3nMAssay Description:PTPN2 was produced in E. coli as a GST-TEV fusion and the GST was removed by TEV digestion, followed by additional purification to yield full-length ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/24/2025
Entry Details
US Patent

TargetReceptor-type tyrosine-protein phosphatase N2 [1-387](Homo sapiens (Human))
Nerio Therapeutics

US Patent
LigandPNGBDBM764784(US20250257059, Example 118)
Affinity DataIC50: 3nMAssay Description:PTPN2 was produced in E. coli as a GST-TEV fusion and the GST was removed by TEV digestion, followed by additional purification to yield full-length ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
11/24/2025
Entry Details
US Patent

Displayed 1 to 50 (of 142 total ) | Next | Last >>
Jump to: